

State of Oklahoma SoonerCare



Rozlytrek® (Entrectinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:		
Billing Provider Information		
Provider NPI: Provider Name:		
	Provider Fax:	
Prescriber Information		
Prescriber NPI: Prescriber Name:		
		Specialty:
Criteria		
For Initial Authorization: 1. Please indicate the diagnosis and Non-Small Cell Lung Cance A. Is disease metastatic? Ye B. Is tumor ROS1-positive? C. Will entrectinib be used as Solid Tumors A. Does diagnosis include Nones None None None None None None None None	er (NSCLC) s No No Yes No No S a single agent? Yes No TRK gene fusion without a know s No Didate? Yes No Ollowing treatment? Yes E therapy available? Yes S single agent? Yes No	own acquired resistance mutation? No No
For Continued Authorization: 1. Date of last dose: 2. Does patient have any evidence of any last the member experienced any lifyes, please specify adverse reaction Additional Information: [of progressive disease while o y adverse drug reactions relate ns:	ed to entrectinib therapy? Yes No
Prescriber Signature:		Date:
		nformation is true and correct to the best of my e requested if necessary. Failure to complete this

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

form in full will result in processing delays.

AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 134 5/23/2023